CTLA4 and neoplasm: Currently, a first clinical CTLA-4 imaging study is ongoing, where tumor lesion uptake and the biodistribution of 89Zr-labeled ipilimumab will be assessed at the start of ipilimumab therapy and after the second injection three weeks later.